FI93216B - Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat - Google Patents

Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat Download PDF

Info

Publication number
FI93216B
FI93216B FI890678A FI890678A FI93216B FI 93216 B FI93216 B FI 93216B FI 890678 A FI890678 A FI 890678A FI 890678 A FI890678 A FI 890678A FI 93216 B FI93216 B FI 93216B
Authority
FI
Finland
Prior art keywords
formula
pyridyl
acid
compound
mixture
Prior art date
Application number
FI890678A
Other languages
English (en)
Finnish (fi)
Other versions
FI93216C (sv
FI890678A0 (sv
FI890678A (sv
Inventor
Michael James Smithers
Andrew George Brewster
George Robert Brown
Reginald Jessup
Alan Wellington Faull
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803516A external-priority patent/GB8803516D0/en
Priority claimed from GB888824666A external-priority patent/GB8824666D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of FI890678A0 publication Critical patent/FI890678A0/sv
Publication of FI890678A publication Critical patent/FI890678A/sv
Application granted granted Critical
Publication of FI93216B publication Critical patent/FI93216B/sv
Publication of FI93216C publication Critical patent/FI93216C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

1. Analogiförfarande för framställning av terapeu-tiskt användbara 1,3-dioxanalkensyraderivat med formeln I 5 H (CH2) n * Y · A1 · CO * R2 R1_I L r°T^<Vx 10. n ^ väri A1 är (l-4C)alkylen; R1 är (l-6C)älkyl, trifluormetyl, (3-6C)cykloalkyl eller (l-4C)alkoxi(1-4C)alkyl eller en grupp med formeln R3A2-, väri R3 är pyridyl, fenyl eller 15 fenyl med 1 eller 2 substituenter, vilka valts bland föl-jande: halogen, trifluormetyl, nitro och cyan, och A2 är (l-4C)alkylen, oxi(1-4C)alkylen, (2-4C)alkenylen eller en direkt bindning till R3; R2 är hydroxi eller (l-4C)alkoxi; X är väte; Y är vinylen; och n är ett heltal 1 eller 2; 20 och deras farmaceutiskt godtagbara salter, känne-t e c k n a t därav, att (a) ett 1,3-dioxan med formeln VII ,,.25 (CH2)n.Y.A1-C0-R2: Ra x (VII) =V> H ΠΓ 11 30 väri den ena av symbolerna R“ och Rb är väte, metyl eller : etyl och den andra är metyl eller etyl, omsätts i närvaro av en syra med ett överskott av en aldehyd med formeln R1*CH0 eller dess hydrat, acetal eller hemiacetal; eller (b) för framställning av sädana föreningar med for- 35 mein I, väri R2 är hydroxi, hydrolyseras en ester med formeln VIII • · 93216 54 H 0^4- (CH2)n-Y-A1-CO-OR6 R1_^ 5 ^ 0 T^k t~X (VIII) väri R6 är (l-6C)alkyl, fenyl eller bensyl, vilka tvä sist-nämnda eventuellt bär 1 eller 2 halogen-, (l-4C)alkyl-10 eller (l-4C)alkoxisubstituenter; varefter, ifall önskas att framställa ett sait av en förening med formeln I, det erhälls i en reaktion med en sädan lämplig bas eller syra som erbjuder en fysiolo-giskt godtagbart jon, eller medelst nägot annat sedvanligt 15 saltbildningsförfarande; och ytterligare, ifall önskas att framställa en optiskt aktiv form av en förening med formeln I, nägot av de ovan anförda förfaranden utförs genom att använda ett optiskt aktivt utgängsmaterial eller den racemiska formen av en 20 förening med formeln 1 resolveras medelst sedvanliga för faranden, varvid i de ovan angivna formlerna R1, R2, A1, X, Y och n betecknar samma som i patentkravets ingress.
2. Förfarande enligt patentkrav 1, känne-t e c k n a t därav, att man framställer en förening som .25 är 4(Z)-6-[(2,4,5-cis)-2-(1-metyl-l-fenoxietyl)-4-(3-pyri-dy1)-1,3-dioxan-5-yl]hexensyra; 4(Z)-6-[(2,4,5-cis)-2-(4-cyanfenyl)-4-(3-pyridyl)-1,3-dioxan-5-yl]hexensyra; 30 4(Z)-6-[(2,4,5-cis)-2-(1-[4-bromfenoxi]-1-metyletyl)-4- (3-pyridy1)-1,3-dioxan-5-y1]hexensyra; 4(Z)-6-[(2,4,5-cis)-2-(l-[3,4-difluorfenoxi]-l-metyletyl)- 4-(3-pyridyl)-l,3-dioxan-5-yl]hexensyra; eller ett farmaceutiskt godtagbart sait av dessa föreningar.
FI890678A 1988-02-16 1989-02-13 Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat FI93216C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8803516 1988-02-16
GB888803516A GB8803516D0 (en) 1988-02-16 1988-02-16 Heterocyclic compounds
GB8824666 1988-10-21
GB888824666A GB8824666D0 (en) 1988-10-21 1988-10-21 Pyridine derivatives

Publications (4)

Publication Number Publication Date
FI890678A0 FI890678A0 (sv) 1989-02-13
FI890678A FI890678A (sv) 1989-08-17
FI93216B true FI93216B (sv) 1994-11-30
FI93216C FI93216C (sv) 1995-03-10

Family

ID=26293498

Family Applications (1)

Application Number Title Priority Date Filing Date
FI890678A FI93216C (sv) 1988-02-16 1989-02-13 Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat

Country Status (24)

Country Link
US (1) US5166213A (sv)
EP (1) EP0329360B1 (sv)
JP (1) JP2812697B2 (sv)
KR (1) KR0145725B1 (sv)
CN (1) CN1040753C (sv)
AR (1) AR246965A1 (sv)
AT (1) ATE109478T1 (sv)
AU (1) AU626534B2 (sv)
CA (1) CA1335816C (sv)
DE (1) DE68917170T2 (sv)
DK (1) DK66989A (sv)
ES (1) ES2057104T3 (sv)
FI (1) FI93216C (sv)
GB (1) GB8901201D0 (sv)
HU (1) HU209700B (sv)
IE (1) IE63825B1 (sv)
IL (1) IL89214A (sv)
MY (1) MY103699A (sv)
NO (1) NO172491C (sv)
NZ (1) NZ227880A (sv)
PH (1) PH26227A (sv)
PL (1) PL158201B1 (sv)
PT (1) PT89703B (sv)
ZW (1) ZW1789A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709794D0 (en) * 1987-04-24 1987-05-28 Ici Plc Heterocyclic acids
IE81170B1 (en) * 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
GB9021571D0 (en) * 1990-10-04 1990-11-21 Ici Plc Heterocyclic acids
EP2363127A1 (en) * 2006-01-18 2011-09-07 Evolva SA PPAR Modulators
EP2150111B1 (en) * 2007-01-18 2016-10-19 Evolva SA Substituted 1,3-dioxanes useful as ppar modulators
US20120142766A1 (en) * 2007-11-21 2012-06-07 Evolva Sa Substituted 1,3-dioxanes and their uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262096D1 (en) * 1981-03-30 1985-03-14 Hoffmann La Roche 1,3-dioxolane derivatives, their preparation, fungicidal agents containing those compounds as active agents and use of such compounds or agents in combating fungi in agriculture and in gardening
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
GB8330120D0 (en) * 1983-11-11 1983-12-21 Ici Plc Chemical process
GB8330099D0 (en) * 1983-11-11 1983-12-21 Ici Plc Cycloalkane derivatives
GB8330094D0 (en) * 1983-11-11 1983-12-21 Ici Plc Diphenyl compounds
US4554011A (en) * 1984-08-24 1985-11-19 Chevron Research Company Herbicidal 2S-(2β,4β,5β)-5-Arylmethoxy-4-substituted 2-alkyl-1,3-dioxane derivatives
GB8511890D0 (en) * 1985-05-10 1985-06-19 Ici Plc Benzene derivatives
US4824858A (en) * 1985-05-10 1989-04-25 Imperial Chemical Industries Plc 1,3-Dioxolane-5-yl-hexenoic acid derivatives
GB8511892D0 (en) * 1985-05-10 1985-06-19 Ici Plc Fluoralkane derivatives
GB8511891D0 (en) * 1985-05-10 1985-06-19 Ici Plc Alkenoic acids
GB8511894D0 (en) * 1985-05-10 1985-06-19 Ici Plc Phenol derivatives
GB8511895D0 (en) * 1985-05-10 1985-06-19 Ici Plc Heterocyclic compounds
HU198706B (en) * 1985-05-10 1989-11-28 Ici Plc Process for producing 1,3-dioxan-ethers and pharmaceutical compositions containing them
GB8611174D0 (en) * 1986-05-08 1986-06-18 Ici Plc Amide derivatives
ATE56967T1 (de) * 1985-11-12 1990-10-15 Ici Plc Amidderivate.
GB8531892D0 (en) * 1985-12-30 1986-02-05 Ici Plc Carboxylic acids
GB8626297D0 (en) * 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8626296D0 (en) * 1986-11-04 1986-12-03 Ici Plc Therapeutic agents
GB8709794D0 (en) * 1987-04-24 1987-05-28 Ici Plc Heterocyclic acids
IE81170B1 (en) * 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives

Also Published As

Publication number Publication date
PT89703B (pt) 1994-04-29
DK66989A (da) 1989-08-17
EP0329360A3 (en) 1990-09-05
IE63825B1 (en) 1995-06-14
IE890392L (en) 1989-08-16
FI93216C (sv) 1995-03-10
DK66989D0 (da) 1989-02-13
CA1335816C (en) 1995-06-06
EP0329360B1 (en) 1994-08-03
NZ227880A (en) 1991-10-25
KR0145725B1 (ko) 1998-08-17
ATE109478T1 (de) 1994-08-15
NO890607L (no) 1989-08-17
IL89214A (en) 1994-01-25
JP2812697B2 (ja) 1998-10-22
DE68917170D1 (de) 1994-09-08
ZW1789A1 (en) 1990-03-21
GB8901201D0 (en) 1989-03-15
KR890013005A (ko) 1989-09-20
DE68917170T2 (de) 1994-12-15
AR246965A1 (es) 1994-10-31
NO172491C (no) 1993-07-28
US5166213A (en) 1992-11-24
PH26227A (en) 1992-04-01
MY103699A (en) 1993-08-28
ES2057104T3 (es) 1994-10-16
PT89703A (pt) 1989-10-04
CN1035115A (zh) 1989-08-30
NO172491B (no) 1993-04-19
AU626534B2 (en) 1992-08-06
FI890678A0 (sv) 1989-02-13
AU2990889A (en) 1989-08-17
CN1040753C (zh) 1998-11-18
NO890607D0 (no) 1989-02-13
FI890678A (sv) 1989-08-17
EP0329360A2 (en) 1989-08-23
HUT54143A (en) 1991-01-28
HU209700B (en) 1994-10-28
PL158201B1 (pl) 1992-08-31
JPH01249770A (ja) 1989-10-05

Similar Documents

Publication Publication Date Title
FI93545C (sv) Analogiaförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat
JP2010043004A (ja) 新規２環性複素環化合物
FI93216B (sv) Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat
FI84602C (sv) Förfarande för framställning av ett terapeutiskt aktivt 2,4-difenyl-1, 3-dioxanderivat
JP2620298B2 (ja) １，３‐ジオキサンアルカノイツク酸誘導体、その製法、これを含有する心臓及び血管の疾病の治療剤及び中間体
US4908380A (en) Pharmaceutical compositions
US5248780A (en) Pyridyl substituted alkenoic acid derivatives
KR100191763B1 (ko) 헤테로시클릭산
US4925869A (en) Therapeutic agents
RU2040525C1 (ru) 1,3-дииоксаноновые производные алкеновой кислоты или их фармацевтически приемлемая соль

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: IMPERIAL CHEMICAL INDUSTRIES PLC